Unwanted

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unwanted

What is Unwanted? Identity and Classification

The medicine Unwanted is defined as an oral pharmaceutical preparation containing a potent synthetic steroid derivative designed to modulate key hormonal pathways in the body. It is formally classified by its mechanism of action as a tool for targeted medical intervention. This description details the drug’s verified identity, classification, and general function, excluding all usage, safety, or regulatory specifics.


Quick Facts: Unwanted (Mifepristone) Identity

Property Description
Active ingredient Mifepristone
Form Tablets
Pharmacological Class Progesterone Receptor Modulator, Antiprogestational Agent
General Purpose Chemical interruption of specific physiological processes
Origin Synthetic Steroid Derivative

What is the Composition and Form of Unwanted?

Unwanted is a single-ingredient medication presented as tablets intended for oral administration. The sole active ingredient is Mifepristone (INN), a compound that chemically derives from the estrane structure, classifying it as a synthetic steroid derivative. Mifepristone possesses high binding affinity for the progesterone receptor. The final preparation consists of Mifepristone combined with solid pharmaceutical excipients that form the inert base of the tablet.

What Type of Medicine is Mifepristone?

Mifepristone is classified pharmacologically as a Progesterone Receptor Modulator and an Antiprogestational Agent. This established classification means the substance achieves its primary effect through hormone receptor blockade, neutralizing the typical biological effects of the hormone progesterone within specific target tissues. This confirms that the medication works by blocking the signals of a key hormone. Unlike medications that either supplement or mimic hormones, this drug acts as an antagonist, physically binding to cellular progesterone receptors and preventing the natural hormone from sending its necessary signal to the cells.

What is the General Purpose of Antiprogestational Agents?

The general purpose of this type of medicine is to achieve a controlled physiological alteration by chemically opposing the critical effects of progesterone. The drug’s core function involves causing the breakdown of the uterine lining (decidua) and promoting the increased sensitivity of the uterine muscle to contractions. Clinically recognized for its essential role in reproductive health, this medicine is typically used in a combined regimen to ensure the complete pharmacological resolution of an intrauterine pregnancy. Mifepristone is included on the Model List of Essential Medicines, acknowledging its established efficacy and general utility in public health systems.

Regulatory References

  1. NIH Mifepristone - StatPearls - NCBI Bookshelf
  2. Mifepristone - StatPearls - NCBI Bookshelf
  3. WHO Essential Medicines - Mifepristone - misoprostol
  4. Mifepristone - misoprostol on WHO eEML

What side effects are possible with Unwanted?

Possible side effects and safety information

The official safety information for Unwanted (Mifepristone) classifies adverse reactions based on incidence reported in clinical trials and organizes them by the affected system-organ class. This regulatory framework ensures that all documented outcomes are communicated in a clear, standardized manner.

Frequency-Classified Adverse Reactions

Adverse reactions that are categorized as very common in regulatory documents often include gastrointestinal effects such as nausea, vomiting, and diarrhea, along with systemic effects like headache, fatigue, and peripheral edema. Effects classified as common include dizziness, somnolence, hypertension, and musculoskeletal discomfort such as back pain and joint pain (arthralgia).

System-Organ Class Examples of Documented Effects
Gastrointestinal Nausea, Vomiting, Diarrhea, Abdominal pain
Nervous System Headache, Dizziness, Somnolence
Metabolism & Nutrition Hypokalemia (low potassium), Decreased appetite
Reproductive System Vaginal bleeding/spotting, Uterine cramping

Serious Safety Considerations

Official government labels specify warnings regarding serious adverse reactions. These include the risk of severe hemorrhage (heavy bleeding) and the potential for serious, sometimes fatal infections, which may present atypically without the usual signs like a high fever. Furthermore, the drug’s use is restricted by certain clinical conditions. For instance, it is generally not recommended for individuals with severe hepatic (liver) impairment and is contraindicated in patients with chronic adrenal failure or hemorrhagic disorders. Regulatory documentation also notes that while vaginal bleeding typically resolves within weeks, it may persist for 30 days or more in a percentage of users.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Unwanted (Mifepristone) focuses on formally documented physiological responses to excessive exposure and severe complications requiring urgent medical intervention. High doses are officially documented to result in a compensatory elevation of ACTH and cortisol within the endocrine system.

The most critical documented risks requiring immediate medical attention are the potential for hypovolemic shock due to hemorrhage and the risk of developing fatal septic shock or sepsis. Regulatory authorities specify precise clinical signs that necessitate urgent medical care. These signs include prolonged heavy vaginal bleeding—defined as soaking two thick, full-size sanitary pads per hour for two consecutive hours—or any evidence of severe infection, such as a sustained fever of 100.4 F or higher lasting more than four hours, accompanied by severe abdominal pain or a racing heart.

In the event that an excessive amount of the medicine has been taken, regulatory guidance instructs individuals to contact a Poison Control center or seek medical help right away. No specific antidote is known for this medicine; therefore, hospital management focuses on supportive measures for complications, which may include the use of uterotonics, saline infusions, blood transfusions, or procedural interventions like curettage. Furthermore, high-dose use carries a specific regulatory constraint, as it is not recommended in severe hepatic impairment.

Therapeutic Uses of Unwanted

What Unwanted Treats: Main Uses and Benefits

The primary therapeutic utility is applied across domains where additional symptomatic support is needed for certain time-sensitive clinical states and complex metabolic conditions. The medicine is commonly used to help with two distinct therapeutic areas.

Managing the Clinical State of Early Pregnancy

This medicine is commonly applied to achieve the medical resolution of an early intrauterine pregnancy, specifically within the first 70 days (10 weeks) of gestation. It generally provides a crucial non-surgical alternative for managing this clinical status and may assist with the expulsion of tissue following a confirmed early pregnancy loss. The benefit contributes to improved comfort during periods of heightened symptoms by supporting the necessary therapeutic process.

Specialized Control of Metabolic Imbalance

It is also utilized in adults with endogenous Cushing syndrome to address conditions marked by pronounced elevation of blood sugar levels (hyperglycemia) and associated glucose intolerance, which are symptoms that create noticeable physiological strain. For these patients, the key benefit assists with maintaining functional stability by supporting the management of challenging blood sugar symptoms.


Quick Fact: Relief for Metabolic Symptoms
Conditions Cushing syndrome (with associated hyperglycemia)
Symptom Goal Management of pronounced high blood sugar levels
Patient Benefit Supports the patient during difficult episodes by easing systemic imbalance

Eligibility and Restrictions for Use

Official Eligibility Profile for Unwanted (Mifepristone)

Official regulatory documents define strict population eligibility for Mifepristone based on specific health conditions, age, and physiological status.

Populations for Whom Use is Contraindicated

Use is prohibited (contraindicated) for individuals with Chronic Adrenal Failure, Inherited Porphyria, or Hemorrhagic Disorders. The medicine must not be used if a patient has a confirmed or suspected Ectopic Pregnancy or an Intrauterine Device (IUD) in place. Additionally, the medicine is contraindicated in patients receiving concurrent long-term corticosteroid therapy.

Restricted and Condition-Based Use

For medical termination, use is strictly limited to an intrauterine pregnancy up to 70 days (10 weeks) of gestation. For the Cushing syndrome indication, the medicine is contraindicated in pregnancy. Patients with severe hepatic impairment are generally not recommended to use the medicine, and dose limitations are mandatory for those with renal or mild-to-moderate hepatic impairment. Safety and efficacy are established in adults; however, safety for non-termination indications is not established in pediatric patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Unwanted (Mifepristone), focusing strictly on regulatory constraints.


Pharmacokinetic and Metabolic Interactions

Unwanted is documented as a moderate inhibitor of the metabolic enzyme CYP3A4, which can lead to increased plasma concentrations (exposure) of co-administered medicines that are primarily metabolized by this enzyme. Conversely, co-administration with substances that are strong CYP3A4 inducers (e.g., Rifampicin, St. John’s Wort) is formally contraindicated because they drastically decrease Unwanted's plasma levels. Administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Grapefruit Juice) is also expected to increase Unwanted’s exposure.


Pharmacodynamic and Timing Constraints

Formal Regulatory Prohibitions include the use of Unwanted by individuals requiring long-term systemic corticosteroid therapy for serious chronic conditions. A mandatory timing rule exists for the co-administered prostaglandin analogue (e.g., Misoprostol), which must be administered 24 to 48 hours after Unwanted to leverage their required additive pharmacodynamic effect. The medicine may also enhance the effects of other substances that prolong the QTc interval.

Mechanism of Action

Modulating Receptor-Mediated Signaling

This domain involves the drug's action as an agonist or antagonist at specific cell-surface or intracellular receptors. By blocking or activating these targets, the drug initiates or suppresses key signaling sequences, contributing to modulation of signaling sequences that influence physiological state.


Regulating Enzyme Activity in Key Pathways

"Unwanted" exerts its effect by directly or allosterically inhibiting or activating specific metabolic enzymes that govern pathway flux. This mechanism modifies early molecular steps within critical biochemical cascades, thereby resulting in reduced concentration or activity of signaling mediators.


Influencing Transmitter and Mediator Availability

This mechanism focuses on the drug's role in altering the synthesis, release, reuptake, or degradation of key endogenous neurotransmitters or other signaling mediators. The resulting effect is a defined alteration in pathway activity that induces changes in activity toward a defined physiological threshold within systems where these mediators dominate.

Dosage and Administration Information

The administration of Mifepristone (Unwanted) is defined by two distinct regimens, each with specific requirements. The medicine is consistently administered via the oral route across all approved uses. For the single-course regimen, such as the medical termination of pregnancy, a 200 mg single oral dose of Mifepristone initiates a sequential therapeutic course. This acute application often requires a pre-administration step, such as the removal of an intrauterine device (IUD).

In contrast, the long-term management of hyperglycemia associated with Cushing syndrome utilizes a maintenance pattern. This chronic use begins with an initial 300 mg dose taken once daily. For this specific regimen, the tablet must be taken with a meal to ensure proper intake. Dosing can be adjusted over time, typically at intervals no sooner than every two to four weeks, up to a maximum daily limit of 1200 mg.

Furthermore, for adult patients with pre-existing mild-to-moderate hepatic or renal impairment in the chronic regimen, the maximum permissible dose is lowered to 600 mg per day. Across both applications, the Mifepristone tablet must always be swallowed whole and should not be crushed, split, or chewed to maintain its integrity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Unwanted (Mifepristone)

This overview summarizes the research that governmental and scientific bodies rely on for the uses of Unwanted (Mifepristone). It focuses on the types of studies conducted and what the findings describe, without offering clinical guidance or advice.


Evidence for the Medical Resolution of Early Pregnancy

The research base for this application draws primarily from Randomized Controlled Trials (RCTs), supported by Systematic Reviews and Meta-analyses. These studies were used in research exploring how outcomes change over defined time intervals. Research examined outcomes related to complete resolution, monitoring whether resolution occurred without the need for surgical intervention. Studies also tracked the timing of the expulsion and the rate of ongoing pregnancy. These findings describe group patterns observed across numerous studies in adults and relevant pediatric patients up to 70 days gestation.


Evidence for Specialized Control of Metabolic Imbalance

The evidence for Unwanted studied for associated symptoms in Cushing Syndrome is based on a single, key, Open-label Clinical Trial, supplemented by historical Case Reports. This research explored changes measured during the study period in a highly specific group of adult patients with hypercortisolism who also had diabetes or hypertension. Researchers examined outcomes where the Global Clinical Response (GCR) score was used to capture systemic imbalance, alongside monitoring shifts in glucose control and blood pressure.


Research Limitations and Follow-up Durations

The follow-up durations for evidence supporting both indications vary. For the medical resolution use, observation periods in main trials were generally intermediate-term (up to two weeks) to confirm resolution status in the studied cohorts. For the metabolic use, the pivotal study monitored responses for 24 weeks (six months). A key limitation is the lack of comparative evidence (no blinded/placebo control) for the metabolic use due to the rarity of the condition and the modest sample sizes. Additionally, research provides limited insight for individuals with certain severe pre-existing comorbidities in the pregnancy resolution studies, as the research base lacks data for these groups.

Key Studies & References WHO Model List of Essential Medicines (Mifepristone inclusion and reproductive health utility)

Frequently Asked Questions (FAQ)

Common questions about Unwanted (FAQ)


Q: How long does it usually take to notice any effect from Unwanted?

Clinical studies show that the effect of Unwanted depends on the regimen being used. For the medical termination of pregnancy regimen, a second medication is taken 24 to 48 hours after Unwanted. Most patients experience the expulsion often occurs within 2 to 24 hours following the second medication.


Q: I heard Unwanted can affect sleep. Is this accurate?

Official documents list somnolence, which is another term for drowsiness, as a common adverse reaction to the medication. Other general effects reported very commonly include fatigue. These central nervous system effects are described in the regulatory safety information.


Q: What kind of monitoring is needed while taking Unwanted?

Regulatory information outlines specific requirements for monitoring. For the termination regimen, a follow-up assessment is generally scheduled approximately 7 to 14 days after the initial dose to confirm the outcome and check for bleeding. For the chronic use regimen, dose adjustments are typically made by a healthcare provider based on ongoing monitoring, no sooner than every two to four weeks.


Q: Can older adults safely use Unwanted?

Safety and effectiveness information is based on studies of the adult population. However, regulatory prescribing information does not generally contain specific guidance or clinical data focused solely on use in the geriatric or older adult population.


Q: Are there any known issues with drinking alcohol while using Unwanted?

While specific instructions regarding alcohol use may vary, official FDA Medication Guides commonly include statements encouraging patients to consult with their healthcare provider about using any non-prescription substances during treatment. Some drug interaction resources indicate a moderate interaction risk between the active ingredient and alcohol.


Q: Is Unwanted classified as a controlled substance?

In the United States, Mifepristone is not currently classified as a controlled substance by the DEA (Drug Enforcement Administration). However, the substance has been historically classified under various schedules by some international regulatory bodies.


Q: Is there a generic version of Unwanted available?

Yes, the FDA has approved generic versions of the active ingredient, Mifepristone. This indicates that a generic alternative is available for patients in the United States.


Q: Does Unwanted affect fertility in men or women?

The medication works by blocking the effects of the hormone progesterone, which can temporarily make it harder to become pregnant while it is in the body. While studies on long-term fertility impact in men are generally not available, official reports describe successful subsequent desired pregnancies following the use of the medicine.


Q: What is the risk of having a serious allergic reaction to Unwanted?

Allergic reactions have been reported following the use of the medication, including a severe, life-threatening allergic reaction called anaphylaxis. The medication is formally contraindicated for use in patients with a known history of allergy to the active ingredient or to the co-administered prostaglandin.


Q: Can I take pain relievers like ibuprofen with Unwanted?

Official Medication Guides often include statements about avoiding the use of other prescription or non-prescription medicines without consulting a healthcare provider, especially when using the termination regimen. This caution is due to potential interactions with other substances, including common pain relievers like NSAIDs.


Q: What are the signs that Unwanted might not be working for me?

For the termination regimen, official information indicates that a lack of any bleeding following treatment is consistent with a potential failure. Additionally, the persistence of heavy or moderate vaginal bleeding at the required follow-up visit (7 to 14 days) may also suggest an incomplete process.


Q: Does Unwanted interact with birth control pills?

Unwanted is classified as a Progesterone Receptor Modulator, meaning it blocks the effects of progesterone, a hormone used in many birth control pills. Due to its mechanism of action and the potential for overlap, official documents generally recommend that patients consult their healthcare provider about using any concurrent hormonal contraception.


Q: How long does Unwanted stay in the system after the last dose?

Studies indicate that the active ingredient, Mifepristone, has a long half-life. For healthy non-pregnant adults, it takes approximately 5 to 20 days on average for most of the medication to be fully eliminated from the body.


Q: Is the medication known to affect mood or anxiety levels?

While studies have examined the active ingredient's effect on mood and sleep disturbance in specialized research settings, specific mood or anxiety changes are not consistently listed as common or very common adverse reactions for its approved indications in the official documentation.


Q: What should I do if I experience a mild side effect from Unwanted?

The FDA Medication Guide contains information encouraging patients to contact their healthcare provider with questions about their treatment or any adverse reactions. Severe symptoms such as a sustained fever, severe abdominal pain, or heavy bleeding are described in the Medication Guide as conditions for which emergency medical attention is necessary.


Q: Are there any specific lifestyle changes recommended when taking Unwanted?

For the long-term use regimen, official information states the tablet should be taken with a meal. For the termination regimen, the Medication Guide advises patients not to take any other prescription, non-prescription, or herbal medicines at any point during the treatment period without first consulting a healthcare provider.


Q: Is Unwanted safe to take with common cold or flu medicines?

Unwanted acts as a moderate inhibitor of the metabolic enzyme CYP3A4. Since many common cold and flu medicines contain active ingredients metabolized by this enzyme, combining them could potentially lead to an increase in the concentration of those medicines. Official information indicates that consultation with a provider is appropriate before combining Unwanted with any common cold or flu medication.


Q: Does Unwanted carry a Boxed Warning?

Yes, the FDA label for the medication does carry a Boxed Warning. This warning is related to the risk of serious and sometimes fatal infections or bleeding following use.


Q: Is Unwanted associated with weight changes?

Clinical trials for the chronic use indication are focused on improving metabolic control, which can impact weight. Adverse reactions that may affect weight, such as decreased appetite and peripheral edema (swelling), are listed, but general weight gain or loss is not explicitly stated as a common side effect.


Q: What makes Unwanted a prescription-only medicine?

The medication is classified as prescription-only because it is subject to a strict Risk Evaluation and Mitigation Strategy (REMS) program. This program is required by the FDA for medications with serious safety concerns and mandates specific distribution and prescribing procedures to ensure its safe use.


Q: What data exists about using Unwanted during breastfeeding?

For the single-dose termination regimen, limited information suggests that interrupting breastfeeding may not be necessary. However, for long-term therapy, the manufacturer's information suggests avoiding breastfeeding and describes pumping and discarding milk during treatment and for up to 18 to 21 days after the last dose due to the drug’s long half-life.


Q: Do official sources describe Unwanted as having potential for misuse?

While the drug is not classified as a controlled substance by the US DEA, the FDA regulates its distribution and use via a strict REMS program. This strategy is typically reserved for medications associated with significant safety concerns requiring specific risk minimization strategies.

How should Unwanted be stored and disposed of?

How to Store and Dispose of Unwanted

The official labeled storage conditions for Unwanted (Mifepristone) tablets require the product be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must not be refrigerated or frozen, and it must be protected from light and moisture.

To ensure product stability, the tablets should be stored in the original container and the container must remain tightly closed. It is mandatory that the medicine be kept out of the reach of children.


Disposal Requirements

Unused, unneeded, or expired medicine must be disposed of according to local regulatory requirements, typically by utilizing a drug take-back program. Regulatory guidance prohibits flushing the tablets down the toilet or throwing them into household trash unless specifically instructed otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unwanted found in:

A-Z Index: